The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA 15-3 are Reliable Biomarkers of Breast Cancer

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 1, 2013, Pages 12-20

  Santillán Benítez, Jonnathan G ^a   Mendieta Zerón, Hugo ^a,b,c   Gómez Oliván, Leobardo M ^a   Torres Juárez, Juan J ^b   González Bañales, Juan M ^b   Hernández Peña, Lorena V ^a   Ordóñez Quiroz, Angel ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^b Maternal Perinatal Hospital Mónica Pretelini Sáenz HMPMPS   (Mexico)

^c Asociación Cientifica Latina ASCILA and Ciprés Grupo Médico CGM   (Mexico)

Author keywords

Biomarker; BMI; Breast cancer; CA 15 3; Leptin

Indexed keywords

ADIPONECTIN; CA 15-3 ANTIGEN; LEPTIN;

ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PROSPECTIVE STUDY; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEPTIN; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; PROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872558688     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21555     Document Type: Article

References (39)

1. Carino C, Olawaiye AB, Cherfils S, Serikawa T, Lynch MP, et al. Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. Int J Cancer 2008;123:2782-2790.
2. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008;68:9712-9722.
3. Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev Engl 2009;10:610-616.
4. Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc 2008;67:128-145.
5. Grossmann ME, Ray A, Nkhata KJ, et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 2010;29:641-653.
6. Awatef M, Olfa G, Kacem M, et al. Association between body mass index and risk of breast cancer in Tunisian women. Ann Saudi Med 2011;31:393-397.
7. Guo S, Liu M, Wang G, et al. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 2012;1825:207-222.
8. Cleary M, Grossmann M, Ray A. Effect of obesity on breast cancer development. Veterinary Pathology Online 2010;47:202-213.
9. Knaul FM, Nigenda G, Lozano R, et al. Breast cancer in Mexico: An urgent priority. Salud Publica Mex 2009;51(Suppl 2):s335-s344.
10. Del Socorro Romero-Figueroa M, Santillan-Arreygue L, Miranda-Garcia M, et al. Epidemiological pattern of breast cancer mortality in Mexico State. Rev Med Inst Mex Seguro Soc 2010;48:253-258.
11. Villaseñor AD. La Obesidad en México. Salud Pública. México: Fundación Este país Conocimiento útil; 2011.
12. Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 2004;64:5870-5875.
13. Cleary MP, Ray A, Rogozina OP, et al. Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed) 2009;1:329-357.
14. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109-114.
15. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. Breast Cancer Res 2011;13:R34. Pp 1-10.
16. Rahmati-Yamchi M, Zarghami N, Rahbani M, et al. Plasma Leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer. Breast Cancer (Auckl) 2011;5:27-35.
17. Conroy SM, Chai W, Lim U, et al. Leptin, adiponectin, and obesity among Caucasian and Asian women. Mediators Inflamm 2011;2011:253-580. Pp 1-7.
18. Cleary MP, Grossmann ME, Ray A. Effect of obesity on breast cancer development. Vet Pathol 2010;47:202-213.
19. Maskarinec G, Woolcott C, Steude JS, et al. The relation of leptin and adiponectin with breast density among premenopausal women. Eur J Cancer Prev 2010;19:55-60.
20. Paz-Filho G, Lim EL, Wong ML, et al. Associations between adipokines and obesity-related cancer. Front Biosci 2011;16:1634-1650.
21. Maccio A, Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: Therapeutic implications. Sci World J 2011;11:2020-2036.
22. Yaw YH, Kandiah M, Shariff ZM, et al. Pattern of weight changes in women with breast cancer. Asian Pac J Cancer Prev 2010;11:1535-1540.
23. Cirillo D, Rachiglio AM, la Montagna R, et al. Leptin signaling in breast cancer: An overview. J Cell Biochem 2008;105:956-964.
24. Fiorio E, Mercanti A, Terrasi M, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008;8:305. Pp 1-11.
25. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001;2:129-135; discussion 36-37.
26. Molina R, Auge JM, Farrus B, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem 2010;56:1148-1157.
27. Pakiz B, Flatt SW, Bardwell WA, et al. Effects of a weight loss intervention on body mass, fitness, and inflammatory biomarkers in overweight or obese breast cancer survivors. Int J Behav Med 2011;18:333-341.
28. Dalamaga M, Archondakis S, Sotiropoulos G, et al. Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas 2012;71:301-308.
29. Perrier S, Caldefie-Chezet F, Vasson MP. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett 2009;583:259-265.
30. Hu X, Juneja SC, Maihle NJ, et al. Leptin-A growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 2002;94:1704-1711.
31. Smirnova OV, Ostroukhova TY, Bogorad RL. JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol 2007;13:6478-6491.
32. Jardé T, Perrier S, Vasson MP, et al. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011;47:33-43.
33. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, et al. Involvement of adiponectin and leptin in breast cancer: Clinical and in vitro studies. Endocr Relat Cancer 2009;16:1197-1210.
34. Duffy MJ, Evoy D, McDermott EW. CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010;411:1869-1874.
35. Lichtman MA. Obesity and the risk of chronic myelogenous leukemia: is this another example of the neoplastic effects of increased body fat? Leukemia 2012;26:183-184.
36. Zhang Y, Liu Z, Yu X, et al. The association between metabolic abnormality and endometrial cancer: A large case-control study in China. Gynecol Oncol 2010;117:41-46.
37. Kaklamani V, Yi N, Sadim M, et al. The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet 2011;12:52.
38. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 2011;104:128-137.
39. Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol 2007;30:1499-1509.